These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Catalysts lie ahead for both of these companies.
Is Iovance Biotherapeutics Stock a Buy Now?
Let's find out if this biotech can keep up its recent momentum.
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
These companies are in the early days of their growth stories.
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
Find out why investment banks up and down Wall Street have big expectations for these stocks.
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
This company's growth story is about to get moving with gusto.
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
Its revenue is set to grow, and one of its trials is no longer paused.
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
With its first approval in hand, attention is now on the top line.
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio?
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
A robust rally ended abruptly with the publication of the company's latest fundamentals.
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?
More gains might be on the way for this high-flying biotech stock.